Abstract
BackgroundPatients with relapsed/refractory T-cell malignancies have limited treatment options. The use of chimeric antigen receptor (CAR)-T cell therapy for T-cell malignancies is challenging due to possible blast contamination of autologous...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have